- Home
- DMAC vs IKT Comparison
DMAC vs IKT Comparison
Compare DMAC & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMAC
- IKT
- Stock Information
- Founded
- DMAC 2000
- IKT 2008
- Country
- DMAC United States
- IKT United States
- Employees
- DMAC N/A
- IKT N/A
- Industry
- DMAC Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- DMAC Health Care
- IKT Health Care
- Exchange
- DMAC Nasdaq
- IKT Nasdaq
- Market Cap
- DMAC 185.1M
- IKT 159.2M
- IPO Year
- DMAC N/A
- IKT 2020
- Fundamental
- Price
- DMAC $4.23
- IKT $3.24
- Analyst Decision
- DMAC Strong Buy
- IKT Strong Buy
- Analyst Count
- DMAC 3
- IKT 1
- Target Price
- DMAC $7.00
- IKT $5.00
- AVG Volume (30 Days)
- DMAC 34.2K
- IKT 318.4K
- Earning Date
- DMAC 11-13-2024
- IKT 11-12-2024
- Dividend Yield
- DMAC N/A
- IKT N/A
- EPS Growth
- DMAC N/A
- IKT N/A
- EPS
- DMAC N/A
- IKT N/A
- Revenue
- DMAC N/A
- IKT $79,570.00
- Revenue This Year
- DMAC N/A
- IKT N/A
- Revenue Next Year
- DMAC N/A
- IKT N/A
- P/E Ratio
- DMAC N/A
- IKT N/A
- Revenue Growth
- DMAC N/A
- IKT N/A
- 52 Week Low
- DMAC $2.12
- IKT $0.80
- 52 Week High
- DMAC $4.95
- IKT $3.82
- Technical
- Relative Strength Index (RSI)
- DMAC 45.24
- IKT 76.96
- Support Level
- DMAC $4.14
- IKT $2.56
- Resistance Level
- DMAC $4.48
- IKT $2.75
- Average True Range (ATR)
- DMAC 0.18
- IKT 0.27
- MACD
- DMAC -0.03
- IKT 0.03
- Stochastic Oscillator
- DMAC 34.88
- IKT 96.43
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is principally engaged in the business activity of developing treatments for unmet clinical needs or where no therapies are available with a primary focus on chronic kidney disease and acute ischemicstroke. Its pipeline product DM199 is a recombinant form of human tissue kallikrein-1.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.